Adrita Chanda1, Adrija Aich1, Arka Sanyal2, Anantika Chandra3 and Saumyadeep Goswami3*
1School of Biosciences and Technology (SBST), Vellore Institute of Technology, Vellore, India 2School of Biotechnology, KIIT University, India 3School of Bioscience, Indian Institute of Technology, Kharagpur, Kharagpur, West Bengal, India
*Corresponding Author: Saumyadeep Goswami, School of Bioscience, Indian Institute of Technology, Kharagpur, Kharagpur, West Bengal, India.
Received: July 04, 2022; Published: July 29, 2022
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in China's Hubei area in late 2019 has now created a global pandemic that has spread to over 150 countries. In most people, COVID-19 is a respiratory infection that produces fever, cough, and shortness of breath. Patients with severe Covid- 19 may develop ARDS. MSCs can come from a number of places, such as bone marrow, umbilical cord, and adipose tissue. Because of their easy accessibility and low immunogenicity, MSCs were often used in animal and clinical research. In recent studies, MSCs have been shown to decrease inflammation, enhance lung permeability, improve microbial and alveolar fluid clearance, and accelerate lung epithelial and endothelial repair. Furthermore, MSC-based therapy has shown promising outcomes in preclinical studies and phase 1 clinical trials in sepsis and ARDS. In this paper, we posit the therapeutic strategies using MSC and dissect how and why MSC therapy is a potential treatment option for COVID-19-induced ARDS. We cite numerous promising clinical trials, elucidate the potential advantages of MSC therapy for Covid-19 ARDS patients, examine the detriments of this therapeutic strategy and suggest possibilities of subsequent research.
Keywords: Mesenchymal Stem Cell Therapy; Covid-19; Acute Respiratory Distress Syndrome; ARDS
Citation: Saumyadeep Goswami, et al. “Current Landscape of Mesenchymal Stem Cell Therapy in COVID Induced Acute Respiratory Distress Syndrome". Acta Scientific Microbiology 5.8 (2022): 149-162.
Copyright: © 2022 Saumyadeep Goswami., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.